Croda stock reports 5 percent H1 sales growth as margins improve

Published on 10/05/2026 at 16:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Croda stock was trading at GBp 3,265 on October 5, 2026, while H1 sales rose 5 percent to GBP 881 million. Management kept 2026 growth guidance at 3-6 percent.

Flatlay mit Aktienzertifikat, ISIN-Karte, Cremetiegeln und Laborfläschchen — Croda International Plc (ISIN GB00BJFFLV09) wird durch Flatlay mit Aktienzertifikat, ISIN-Karte und Laborutensilien dargestellt, Illustration mit AI erstellt.

Croda stock (ISIN GB00BJFFLV09) was trading at GBp 3,265 on October 5, 2026 at 3:01 p.m. BST, down 0.40 percent on the session. The latest company update points to H1 sales growth of 5 percent and a 7 percent increase in adjusted operating profit.

H1 growth improves profitability

According to Yahoo Finance on July 28, 2026, Croda reported constant-currency sales of GBP 881 million for the first half of fiscal 2026, up 5 percent. Adjusted operating profit rose 7 percent to GBP 156 million, adjusted earnings per share increased 9 percent to GBP 0.78, and free cash flow reached GBP 38 million compared with GBP 28 million in the prior-year period.

The mix behind the result matters. Consumer Care sales increased 8 percent, Pharma Ingredients rose 7 percent, and Beauty Actives grew 27 percent in the second quarter. Pharma Solutions remained the weaker point because project timing affected first-half revenue, although management said its order book supports better project revenue in the second half.

Guidance stays at 3 to 6 percent

Croda retained its 2026 outlook after the July 28, 2026 half-year results. The company continues to target organic sales growth of 3-6 percent and further improvement in adjusted operating margin.

The operating trend gives that guidance a measurable base. Adjusted margin improved from 17.2 percent to 17.7 percent in the first half, while transformation savings contributed GBP 18 million during the period and cumulative benefits reached GBP 46 million. For investors, the key test is whether stronger Consumer Care demand and a recovery in Pharma Solutions can support the planned second-half margin progression.

Analysts see limited upside

MarketBeat reported a Moderate Buy consensus from five analysts on October 3, 2026, with an average price target of GBp 3,490 and a target range of GBp 3,200 to GBp 4,000. The average target lies 6.9 percent above the GBp 3,265 price, while the 200-day moving average stood at GBp 3,042.03.

Stock remains below yearly high

Croda stock was trading at GBp 3,265 on the London Stock Exchange on October 5, 2026. The 52-week range was GBp 2,488 to GBp 3,520.24, and market capitalization stood at GBP 4.5 billion.